Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 300 IN PLASTIC CONTAINER versus MD 76R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 300 IN PLASTIC CONTAINER versus MD 76R.
IOPAMIDOL-300 IN PLASTIC CONTAINER vs MD-76R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a non-ionic, low-osmolality iodinated contrast agent that increases the radiopacity of vascular structures and tissues by attenuating X-rays. It distributes into the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
MD-76R is a radiopaque contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast of blood vessels and tissues during radiographic procedures. It functions by increasing the absorption of X-rays in areas where it is present, allowing for visualization of vascular structures and organ perfusion.
Intravenous administration: 1-2 mL/kg (300-600 mg iodine/kg) for contrast imaging; maximum 200 mL per procedure.
2–4 mL/kg intravenously, maximum 150 mL per procedure.
None Documented
None Documented
Approximately 2 hours in patients with normal renal function (GFR >90 mL/min). Prolonged in renal impairment (up to 30 hours or more in severe disease).
Terminal half-life 1-2 hours; prolonged in renal impairment.
Primarily renal via glomerular filtration; >95% eliminated unchanged in urine within 24 hours. Biliary/fecal elimination is negligible (<1%).
Primarily renal; 95% eliminated unchanged in urine within 24 hours; <1% fecal.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent